Research Topics
| JULIA L contact HURWITZSummaryAffiliation: St. Jude Children's Research Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Epstein-Barr virus vaccine development: a lytic and latent protein cocktailTimothy D Lockey
Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
Front Biosci 13:5916-27. 2008..Results encourage further development of the cocktail vaccine strategy as a potentially powerful weapon against EBV infection and disease in humans...
Respiratory syncytial virus: current progress in vaccine developmentRajeev Rudraraju
Department of Infectious Diseases, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
Viruses 5:577-94. 2013..The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches...
Respiratory syncytial virus vaccine developmentJulia L Hurwitz
Department of Infectious Diseases, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
Expert Rev Vaccines 10:1415-33. 2011..The development of a successful RSV vaccine may ultimately stem from attention to historical lessons, in concert with an integral partnering of immunology and virology research fields...
Application of the polyvalent approach to HIV-1 vaccine developmentJulia L Hurwitz
Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
Curr Drug Targets Infect Disord 5:143-56. 2005..Information presented in this review highlights the potential and importance of the polyvalent vaccine approach for the future development of an effective HIV-1 vaccine...
Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infectionsJulia L Hurwitz
Department of Infectious Diseases, St Jude Children s Research Hospital, and Department of Pathology, University of Tennessee, Memphis, TN 38105, USA
Pediatr Infect Dis J 27:S126-8. 2008..As clinical safety studies progress, St. Jude Children's Research Hospital researchers are also working to formulate a SV-based cocktail vaccine designed to prevent several hPIV and RSV infections in humans...
HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktailJulia L Hurwitz
Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
Front Biosci 13:609-20. 2008..The SJCRH multi-vectored, multi-envelope vaccine has now been shown to elicit HIV-1-specific B- and T-cell functions with a diversity and durability that may be required to prevent HIV-1 infections in humans...
Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforinSherri L Surman
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, USA
AIDS Res Hum Retroviruses 26:783-93. 2010..Taken together, our results showed that HIV-1 envelope recombinant virus clearance was dependent on CD4(+) T cells and IFN-gamma, but occurred in the absence of B cells, CD8(+) T cells, or perforin...
Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSVBart Jones
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
Vaccine 27:1848-57. 2009..Results identify SeV vectors as promising vaccine candidates for four different paramyxoviruses, each responsible for serious respiratory infections in children...
Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsXiaoyan Zhan
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
Vaccine 26:3480-8. 2008..Results encourage the continued development of the candidate recombinant SeV vaccines to combat serious respiratory infections of children...
HIV vaccine rationale, design and testingKaren S Slobod
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
Curr HIV Res 3:107-12. 2005..Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific B-cell and T-cell responses, are reviewed...
Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BXiaoyan Zhan
Department of Infectious Diseases, St Jude Children s Research Hospital, 332N Lauderdale, Memphis, TN 38105, United States
Vaccine 25:8782-93. 2007..Together, experimental results encourage promotion of this recombinant SV construct as a vaccine candidate for the prevention of RSV in humans...
Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activityScott A Brown
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
J Immunol 171:4140-8. 2003..To explain the clustering of Th cell epitopes, we propose that localization of peptide on exposed envelope surfaces facilitates proteolytic activity and preferential peptide shuttling through the Ag processing pathway...
A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoproteinScott A Brown
Department of Immunology, Memphis, TN 38105, USA
J Virol 81:12535-42. 2007....
HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulationsXiaoyan Zhan
Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 23:471-6. 2007..These results emphasized the important influence that envelope peptide position may have on antigen processing, and the consequent impact such processing may have on HIV-1-specific CD4(+) and CD8(+) T-cell activities...
Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIVXiaoyan Zhan
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
Vaccine 23:5306-20. 2005..The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives...
HIV vaccines: brief review and discussion of future directionsKaren S Slobod
Department of Infectious Diseases, St Jude Children s Research Hospital, MS 320 332 N Lauderdale, Memphis, TN 38105, USA
Expert Rev Vaccines 4:305-13. 2005..This article reviews data relevant to the development of cocktail vaccines which have been designed to elicit a wide range of envelope glycoprotein-specific B- and T-cell responses...
Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adultsKaren S Slobod
Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
Vaccine 22:3182-6. 2004..Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children...
Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cellsXiaoyan Zhan
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
Vaccine 22:1206-13. 2004..Our results illustrate the flexibility and durability of immune responses toward individual components of mixed envelope vaccines and encourage the continued development of vaccine cocktails for the control of HIV...
Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccineRobert Sealy
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, USA
Int Rev Immunol 28:49-68. 2009..Preliminary analyses demonstrate early proof-of-principle that a multi-envelope vaccine can elicit neutralizing antibody responses toward heterologous HIV-1 in humans...
CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?Scott A Brown
Deparment of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
Curr Drug Targets Infect Disord 5:113-9. 2005..Since CTL contribute to the success of vaccines in other model systems, an understanding of the strengths and possible limitations of these cells may be critical to future successes in the HIV-1 vaccine field...
First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participantsJulia L Hurwitz
Department of Immunology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
AIDS 22:149-51. 2008..Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant...
HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogenSherri L Surman
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
Hum Vaccin 5:268-71. 2009..Here we describe current efforts to gain insights from other vaccine fields and to adopt a cocktail vaccine approach for the prevention of HIV-1 infections in humans...
Short communication: The dead cell: a potent escort for HIV type 1 transinfectionRobert Sealy
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 25:1123-8. 2009..The fact that dead cells or membranes can support this activity may explain, at least in part, the high frequency of human HIV-1 infections at sites of tissue damage...
SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?Robert Sealy
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
Curr HIV Res 7:497-503. 2009..Perhaps this protective state may serve as a 'gold-standard' for HIV-1 vaccine development, as a similar degree of protection against immunodeficiency virus infections in humans would be much desired...
A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?Timothy D Lockey
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 18:1141-4. 2002..The remaining positions may be empty, or may be associated with a second, perhaps unrelated, peptide moiety...
A highly sensitive single-cell assay detects T-helper cell responses missed by conventional interleukin-2-based methodsSherri Surman
Department of Immunology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794, USA
J Immunol Methods 260:279-83. 2002....
Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSVToru Takimoto
St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
J Virol 78:6043-7. 2004..RSV G-recombinant SV is thus a promising live virus vaccine candidate for RSV...
T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometryScott A Brown
Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 21:165-70. 2005..Results are consistent with the suggestion that gp120 peptide location influences antigen processing, which, in turn, influences the specificity of immunodominant T cells...
Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activitiesRobert Sealy
Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
Clin Vaccine Immunol 15:713-9. 2008..The results highlight potential influences of peptide context on T-cell reactivation by HIV-1 and encourage the continued study of antigen processing as support for improved vaccine design...
Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigensRobert Sealy
Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA
Immunology 108:431-9. 2003..The response towards Sendai virus exhibits neither the early appearance of anti-glycoprotein AFC expressing IgA in draining lymph nodes, nor the subsequent relative deficit of this specificity from bone marrow AFC populations...
Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virusToru Takimoto
Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA
Viral Immunol 18:255-66. 2005..Sendai virus may prove an enormously valuable vaccine platform, permitting the delivery of recombinants targeting important pediatric respiratory pathogens, RSV chief among them...
HIV vaccine discovery and developmentJulia L Hurwitz
Curr Drug Targets Infect Disord 5:81-3. 2005
The HIV pandemic: a forgotten crisis?Maxwell Madzikanga
HIV AIDS Programme, Africa University, Old Mutare, Zimbabwe
Curr Drug Targets Infect Disord 5:85-6. 2005..The devastation caused by HIV and AIDS has touched virtually every world region. One concern is that the unrelenting nature of the HIV pandemic fosters a disposition, not of fear and determination, but of tolerance and complacency...
Research Grants
- Influence of maternal antibodies on a Sendai virus-vectored RSV vaccineJULIA L contact HURWITZ; Fiscal Year: 2010..Data from these experiments will have broad application to the pediatric vaccine field, and will be critical to the launch of clinical trials with rSeV-RSV-F. ..
- DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINEJULIA HURWITZ; Fiscal Year: 2004..Project 4 (K. Slobod) builds on these studies, initiating clinical trials of the safety and effectiveness of vaccines comprised of combinations of immunogenic envelopes. ..
- MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERYJULIA HURWITZ; Fiscal Year: 2001..Jude Children's Research Hospital (SJCRH), predicting successful implementation of the proposed studies. ..
- MARROW TRANSPLANT IN CANCER THERAPY--T-CELL RECOVERYJULIA HURWITZ; Fiscal Year: 1993....
- HIV-envelope-specific CD4+ T-cell activation and functional potentialsJulia L Hurwitz; Fiscal Year: 2010..Results from these experiments may be invaluable to the construction of new, successful HIV-1 vaccines designed to capture the full potentials of the immune response. ..
